Antitumor Efficacy of 34.5ENVE: A Transcriptionally Retargeted and “Vstat120”-expressing Oncolytic Virus
Ji Young Yoo(The University of Texas MD Anderson Cancer Center), Balveen Kaur(Augusta University), Amy Haseley(Neurological Surgery), Kimerly Powell(The Ohio State University), Jianying Zhang(Shanxi Agricultural University), Anna Bratasz(The Ohio State University Wexner Medical Center), E. Antonio Chiocca(Center for Cancer Research)
Cited by 58
Related Papers
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
|Science Advances|2018|614
Multiplexed Profiling of Single Extracellular Vesicles
|ACS Nano|2017|372
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
|Proceedings of the National Academy of Sciences|2006|360